Mostrar o rexistro simple do ítem

dc.contributor.authorRodríguez-Míguez, Eva
dc.contributor.authorCasal, Bruno
dc.contributor.authorRivera, Berta
dc.date.accessioned2024-01-12T15:43:41Z
dc.date.issued2021
dc.identifier.citationEva Rodríguez-Míguez, Bruno Casal & Berta Rivera (2021) Measuring health-related quality of life in patients treated for substance dependence: differences among instruments and methods of eliciting preferences, Expert Review of Pharmacoeconomics & Outcomes Research, 21:4, 683-690, DOI: 10.1080/14737167.2020.1804872es_ES
dc.identifier.issn1473-7167
dc.identifier.issn1744-8379
dc.identifier.urihttp://hdl.handle.net/2183/34885
dc.description.abstract[Abstract] Background: Measuring the health-related quality of life is an essential estimation in cost–utility studies. In this research, we provide new evidence about comparing utility scores – in the field of substance dependence. Although the main objective is to compare the EQ-5D-5L and SF-6D with paired gamble, evidence about the SF-6D with standard gamble is also provided. Methods: Ninety-four patients with substance dependence were recruited; the SF-6D and the EQ-5D-5L were administered at the beginning of treatment and 6 months thereafter. Differences in treatment effect were estimated by comparing utility gains. All analyses were reproduced for two subgroups of severity. Results: Both the baseline scores and the treatment effect are sensitive to the instrument used. For severe states, the SF-6D with paired gamble (SF-6D with standard gamble) estimates the lowest (highest) utility. With regard to the impact of treatment, the EQ-5D-5L and SF-6D with paired gamble estimate strongly similar effects for severe states (and both estimate greater effects than does the SF-6D with standard gamble). Conclusions: These findings have implications for cost–utility analyses. The incremental cost-utility ratio of treatments intended for severe states is barely sensitive to the choice of EQ-5D-5L or SF-6D with paired gamble.es_ES
dc.description.sponsorshipThis study was funded by the Spanish Ministry of Health, Social Services and Equality [Grant no. 2013I027] and by the Spanish Ministry of Science, Innovation and Universities and FEDER [Grant RTI2018-099403-B-I00]es_ES
dc.description.sponsorshipMinisterio de Sanidad, Servicios Sociales e Igualdad; 2013I027es_ES
dc.language.isoenges_ES
dc.publisherTaylor & Francises_ES
dc.relationinfo: eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/RTI2018-099403-B-I00/ES/ESTUDIOS EMPIRICOS DE ECONOMIA INDUSTRIAL Y ECONOMIA DE LA SALUD. APLICACIONES CON DATOS MICROECONOMICOSes_ES
dc.relation.urihttps://doi.org/10.1080/14737167.2020.1804872es_ES
dc.rights© 2020 Informa UK Limited, trading as Taylor & Francis Groupes_ES
dc.subjectEQ-5D-5es_ES
dc.subjectSF-6Des_ES
dc.subjectPaired gamblees_ES
dc.subjectStandard gamblees_ES
dc.subjectSubstance dependencees_ES
dc.subjectQuality of lifees_ES
dc.titleMeasuring Health-Related Quality of Life in Patients Treated for Substance Dependence: Differences Among Instruments and Methods of Eliciting Preferenceses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate9999-99-99es_ES
dc.date.embargoLift10007-06-07
UDC.journalTitleExpert Review of Pharmacoeconomics & Outcomes Researches_ES
UDC.volume21es_ES
UDC.issue4es_ES
UDC.startPage683es_ES
UDC.endPage690es_ES
dc.identifier.doihttps://doi.org/10.1080/14737167.2020.1804872


Ficheiros no ítem

Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem